Vetr Inc. upgraded Rite Aid Corporation (NYSE:RAD) to Strong-Buy in a report released today.
- Updated: September 30, 2016
Only yesterday Rite Aid Corporation (NYSE:RAD) traded 1.59% higher at $7.72. Rite Aid Corporation’s 50-day moving average is $7.79 and its 200-day moving average is $7.70. The last stock close price is up -0.19% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Trading volume was down over the average, with 13,135,117 shares of RAD changing hands under the typical 16,440,200
Vetr Inc. has upgraded Rite Aid Corporation (NYSE:RAD) to Strong-Buy in a statement released on 9/30/2016.
Rite Aid Corporation has 52 week low of $5.98 and a one year high of $8.74 with a PE ratio of 59.61 and has a total market value of $0.
A total of 9 brokers have released a ratings update on RAD. 1 firm rating the company a strong buy, five brokers rating the stock a buy, 5 brokerages rating the company a hold, zero firms rating the stock a underperform, and finally 0 brokers rating the stock a sell with a one year target of $9.00.
General Company Details For Rite Aid Corporation (NYSE:RAD)
Rite Aid Corporation is a retail drugstore chain. The Company's segments include Retail Pharmacy and Pharmacy Services. The Company operates under The Rite Aid name. It operates approximately 4,560 stores in over 30 states across the country and in the District of Columbia. The Company's Retail Pharmacy segment consists of Rite Aid stores, RediClinic and Health Dialog. It sells brand and generic prescription drugs, as well as an assortment of front-end products, including health and beauty aids, personal care products, seasonal merchandise, and a private brand product line. Its front-end products include over-the-counter medications, health and beauty aids, personal care items, cosmetics, household items, food and beverages, greeting cards, seasonal merchandise and numerous other everyday and convenience products. The Company's Pharmacy Services segment consists of EnvisionRx, which provides a range of pharmacy benefit services.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.